What Traws Pharma Inc's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 1 |
| Sells | 0 | 0 |
| Total trades | 0 | 11 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 728,777 |
| Disposed | 0 | 0 |
| Net activity | +0 | +728,777 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Orbimed Advisors Llc | 10% owner | Apr 16 | Open-market buy · P | +597,729 | $1.67 | +$998K | 1,203,250 |
| Redfield Robert | Chief Medical Officer | Dec 12 | Grant / award · A | +16,419 | — | — | 113,919 |
| Savchuk Nikolay | Chief Operating Officer | Dec 12 | Grant / award · A | +16,419 | — | — | 150,606 |
| Dukes Iain D. | Chief Executive Officer | Dec 12 | Grant / award · A | +36,943 | — | — | 171,130 |
| Pauza Charles David | Chief Science Officer Virology | Dec 12 | Grant / award · A | +18,471 | — | — | 115,971 |
| Shoemaker Mary Teresa | Director | Dec 12 | Grant / award · A | +6,157 | — | — | 6,292 |
| Stover Jack E | Director | Dec 12 | Grant / award · A | +6,157 | — | — | 6,165 |
| Cautreels Werner | Director | Dec 12 | Grant / award · A | +4,874 | — | — | 109,222 |
| Clarke Trafford | Director | Dec 12 | Grant / award · A | +6,157 | — | — | 6,157 |
| Leaman John Harold | Director | Dec 12 | Grant / award · A | +4,058 | — | — | 4,058 |
| Parker Charles Nolan | Chief Financial Officer | Dec 12 | Grant / award · A | +15,393 | — | — | 15,393 |
| TPAV, Llc | 10% owner | Apr 02 | Other Transaction · J | −605,531 | — | — | 0 |
| Cautreels Werner | Chief Executive Officer | Feb 18 | Exercise / conversion · M | +96,348 | $0.01 | +$963 | 104,348 |
| Guerin Mark Patrick | CFO | Jun 18 | Withheld — tax / exercise cost · F | −2,221 | $0.47 | −$1.04K | 39,255 |
| Guerin Mark Patrick | CFO | Jun 10 | Exercise / conversion · M | +5,500 | — | — | 41,476 |
| Cautreels Werner | Chief Executive Officer | Apr 01 | Grant / award · A | +200,000 | — | — | 200,000 |
| Pauza Charles David | Chief Science Officer Virology | Apr 01 | Grant / award · A | +97,500 | — | — | 97,500 |
| Redfield Robert | Acting Chief Medical Officer | Apr 01 | Grant / award · A | +97,500 | — | — | 97,500 |
| Savchuk Nikolay | Chief Operating Officer | Apr 01 | Grant / award · A | +67,500 | — | — | 134,187 |
| Dukes Iain D. | Executive Chairman | Apr 01 | Grant / award · A | +67,500 | — | — | 134,187 |
Loading...
